CN104188939A - Partial external patch containing lidocaine or pharmaceutical salts thereof - Google Patents
Partial external patch containing lidocaine or pharmaceutical salts thereof Download PDFInfo
- Publication number
- CN104188939A CN104188939A CN201410411547.0A CN201410411547A CN104188939A CN 104188939 A CN104188939 A CN 104188939A CN 201410411547 A CN201410411547 A CN 201410411547A CN 104188939 A CN104188939 A CN 104188939A
- Authority
- CN
- China
- Prior art keywords
- preparation
- lignocaine
- pharmaceutical salts
- external patch
- local anesthesia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a partial external patch containing lidocaine or pharmaceutical salts thereof. The invention provides an external preparation of partial drug delivery, wherein an adhesive layer is laminated on a soft back liner; the adhesive layer contains styrene-isoprene-styrene segmented copolymer (SIS), tackifier resin and softer; and lidocaine as the effective component is mixed in the adhesive layer. Compared with the prior art, the preparation provided by the invention has the advantages that the transdermal absorption rate of medicines is increased; the medicines can permeate complete skin to reach a corium layer, so that superficial analgesia is realized; the medicinal effect can be generated within a short time; the particial anaesthesia effect of medicines can be achieved more rapidly; and the partial external patch provided by the invention takes effect rapidly and has good effect.
Description
Technical field
The present invention relates to a kind of local anesthesia external patch tablet, be specifically related to a kind of local anesthesia external patch tablet that contains lignocaine or its pharmaceutical salts and preparation method thereof.
Background technology
Pain is a kind of intrinsic subjective feeling of human body, and it is not only a kind of simple sensation, still has the combined reaction process of impression, emotion, cognition and behavior simultaneously.Child's pain refers to that the individuality that occurs in child is felt or serious uncomfortable sensation appears in readme.Blood drawing and venous cannulation the most often cause hospitalized child pain, in addition to anesthesia, medical personnel fear, often cry and scream, uncooperative, although practice guideline can adopt local anaesthesia before being recommended in venous cannulation, yet that uses at present clinically mostly is ointment, liquid preparation, when using ointment or liquid preparation, have the shortcomings such as clothes of making dirty after the finger of pollution, administration, result can cause skin or the mucosa contact medicine outside medicine-feeding part, makes the uncomfortable situations such as this position sensory paralyses.Therefore, need to provide the medicine that has fine pain palliation efficacy novel form in part, realize in operation process infant painless, without frightened, noxious stimulation is forgotten, suppress pernicious reflection.
The external use plaster that carries out local anesthesia of the approach by percutaneous dosing has caused people's concern in recent years, has carried out up to now trial repeatedly.
For example, patent documentation 1(application publication number CN 101966170 A) compound lidocaine paster of recording in need to first be prepared compound lidocaine emulsion medicament, then preparation attaches and enclosure portion, attach part by ring-type foam tape water-absorption fiber sheet and liner through heat seal, gluing forming, preparation technology is more complicated, loaded down with trivial details, realizes suitability for industrialized production more difficult.Patent documentation 2(application publication number CN 101861148 A) a kind of lignocaine lactate that contains of recording in is as the transdermal formulation of main active, the crystal that utilizes lactic acid to suppress lignocaine is separated out, at embodiment, use solvent application method and heat seeling coating method, if use solvent application method can use a large amount of organic reagents in preparation process, if organic reagent reclaims not exclusively, can cause very large pollution to environment; Use heat seeling coating method, need the temperature of heating to control and strict, because lactic acid heat under normal pressure, can decompose, so that lactic acid production reduction, thereby may cause the crystal of lignocaine to be separated out.
The preparation that the lignocaine content that at present commercially available lignocaine local anaesthesia external patch tablet is day eastern electrician's pharmaceutical manufacturing is 60%, but have that medicament contg is excessive, preparation stability is bad, the easy crystallization of medicine, in the shallow epidermis skin of anesthesia, have drug percutaneous and enter into blood and bring cardiopalmus, hypotension, arrhythmia, bradycardia, conduction block for patient; The problem of the series of side effects such as convulsions, tinnitus, glad, dizzy, nauseating, vomiting, tired, paraesthesia, amyostasia, anxiety, diplopia, respiration inhibition, simultaneously, medicament contg has too much caused high, the discarded paster agent of a large amount of wastes, production cost because the dose that contains high concentration can produce very large risk, medicament contg is crossed conference and is caused medicine in substrate, to occur oversaturated phenomenon, through time shelf stability poor.The inventor has found that by concentrating on studies a kind of special substrate forms, this matrix components can be down to 5%-10%'s by the content of principal agent, simultaneously, drug level is higher in same time release than the drug level of commercially available product 60%, vitro skin transit dose is high, can quick acting, because medicament contg is low, greatly reduce medicine and enter some row side effect that blood brings, when guaranteeing anaesthetic effect, this product has reduced the consumption of principal agent, reduced cost, reduced the side effect of principal agent, reduced the destruction of principal agent composition to environment in the paster after finishing using simultaneously.This preparation process of while is in realizing industrial amplification production, and the preparation that this technique makes is through study on the stability, shows that significant change does not all occur indices, and constant product quality illustrates that the composition and engineering of said preparation is reasonable, stablizes.
Summary of the invention
Object of the present invention, the problem lignocaine local anesthesia patch complex production process solving, suppress the problem of lignocaine crystallization, object is to obtain the local anesthesia external use plaster that lignocaine, skin irritation are little, rapid-action, viscosity is suitable, practicality good, other side effect are little that contains less amount or lower concentration.
The present invention is achieved through the following technical solutions:
A kind of local anesthesia external patch tablet that contains lignocaine or its pharmaceutical salts and preparation method thereof, it is the local applied paster agent of lamination adhesive layer on soft backing, described adhesive phase contains the styrene isoprene styrene block copolymer (SIS) SIS of 10～50 % by weight by weight percentage, the softening agent of the tackifying resin of 20～50 % by weight, 10～50 % by weight, antioxidant, filler, as lignocaine 5～10 % by weight of effective ingredient; Wherein the concrete model of SIS is a kind or the mixture of 2 kinds in JSR5505P or JSR5000.
Wherein, to contain be the MENTHOL of 1～5 % to described adhesive phase by weight percentage.
Wherein, described tackifying resin is the mixture of alicyclic saturated hydrocarbon resin or terpene resin and hydrogenated rosin glyceride, and the two ratio is by weight 1:1～10:1.
Wherein, described softening agent is the mixture of liquid paraffin or liquid paraffin and polybutene, and the two ratio is by weight 3:1～10:1.
Wherein, described antioxidant comprises any one in 2,6-toluene di-tert-butyl phenol BHT or vitamin E.
Wherein, described filler comprises in titanium dioxide, silicon dioxide, zinc oxide, calcium carbonate, Kaolin the mixture of one or two or more kinds.
The preparation method of the local anesthesia external patch tablet that preparation right contains lignocaine or its pharmaceutical salts, containing having the following steps:
(1) the concrete model of getting the styrene isoprene styrene block copolymer (SIS) SIS of recipe quantity is JSR5505P or JSR5000, tackifying resin, softening agent, MENTHOL, antioxidant and filler, controlling temperature is 120 ℃-200 ℃, heating for dissolving, is uniformly mixed and makes mastic A;
(2) principal agent is dissolved in above-mentioned mastic A, is uniformly mixed and makes mastic B;
(3) mastic B is uniformly coated on polyethylene terephtalate film, after looped fabric as preparation backing or non-woven fabrics laminating, the size that severing becomes to set, obtains wanted preparation.
Wherein, PET film is the film that silicon is processed.
Wherein, the temperature of heating for dissolving is 150 ℃-180 ℃.
Wherein, lignocaine pharmaceutical salts comprises lidocaine hydrochloride or lignocaine carbonate.
Accompanying drawing explanation
The skin of abdomen permeability comparison diagram of 1 pair of plucked bar horse miniature pig of Fig. 1 embodiment 1,3 and comparative example.
The permeability comparison diagram of 1 couple of external apery skin Strat-Membrane of Fig. 2 embodiment 1,3 and comparative example.
The comparison diagram of Fig. 3 embodiment 1,3 and comparative example 1 external accumulative releasing degree in pH4.0 buffer is molten.
Fig. 4 embodiment 1,3 and 180 ° of peeling force comparison of test results figure of comparative example 1 steel adhesiveness (collection of illustrative plates is embodiment 3 result figure, embodiment 1 result figure, comparative example 4 result figure from top to bottom).
Embodiment
Below by embodiment, comparative example and test example, further illustrate the present invention.Yet be to be understood that the present invention is not limited to these embodiment.
Embodiment 1
The SIS that to get percentage by weight and be 35.9% model be JSR5505P, 18% terpene resin, 4% hydrogenated rosin glyceride, 25% liquid paraffin, 0.1% BHT, 5% polybutene, 2% MENTHOL are to blending tank, controlling temperature is 120 ℃, heating for dissolving, is uniformly mixed and makes mastic; 10% lignocaine is dissolved in above-mentioned mastic, is uniformly mixed and makes ointment-containing body; Ointment-containing body is uniformly coated on the polyethylene terephtalate film of processing through silicon, after looped fabric or non-woven fabrics laminating as preparation backing, the size that severing becomes to set, obtains wanted preparation.
Embodiment 2
The SIS that the SIS that to get percentage by weight and be 25% model be JSR5505P and 25% model are JSR5000,16% terpene resin, 4% hydrogenated rosin glyceride, 15% liquid paraffin, 0.1% BHT, 5% polybutene, 3% MENTHOL are to blending tank, controlling temperature is 150 ℃, heating for dissolving, is uniformly mixed and makes mastic; 6.9% lignocaine is dissolved in above-mentioned mastic, is uniformly mixed and makes ointment-containing body; Ointment-containing body is uniformly coated on the polyethylene terephtalate film of processing through silicon, after looped fabric or non-woven fabrics laminating as preparation backing, the size that severing becomes to set, obtains wanted preparation.
Embodiment 3
The SIS that to get percentage by weight and be 23.9% model be JSR5505P, 36% terpene resin, 4% hydrogenated rosin glyceride, 20% liquid paraffin, 0.05% vitamin E, 2% polybutene, 4% MENTHOL, 0.05% calcium hydroxide are to blending tank, controlling temperature is 150 ℃, heating for dissolving, is uniformly mixed and makes mastic; 10% lignocaine is dissolved in above-mentioned mastic, is uniformly mixed and makes ointment-containing body; Ointment-containing body is uniformly coated on the polyethylene terephtalate film of processing through silicon, after looped fabric or non-woven fabrics laminating as preparation backing, the size that severing becomes to set, obtains wanted preparation.
Embodiment 4
The SIS that the SIS that to get percentage by weight and be 15% model be JSR5505P and 25% model are JSR5000,30% alicyclic saturated hydrocarbon resin, 20% liquid paraffin, 0.1% BHT, 2% MENTHOL are to blending tank, controlling temperature is 200 ℃, heating for dissolving, is uniformly mixed and makes mastic; 7.9% lignocaine is dissolved in above-mentioned mastic, is uniformly mixed and makes ointment-containing body; Ointment-containing body is uniformly coated on the polyethylene terephtalate film of processing through silicon, after looped fabric or non-woven fabrics laminating as preparation backing, the size that severing becomes to set, obtains wanted preparation.
Embodiment 5
The SIS that to get percentage by weight and be 31.9% model be JSR5000,24% terpene resin, 8% hydrogenated rosin glyceride, 26% liquid paraffin, 0.1%gBHT, 5% MENTHOL are to blending tank, controlling temperature is 120 ℃, heating for dissolving, is uniformly mixed and makes mastic; 5% lidocaine carbonate is dissolved in above-mentioned mastic, is uniformly mixed and makes ointment-containing body; Ointment-containing body is uniformly coated on the polyethylene terephtalate film of processing through silicon, after looped fabric or non-woven fabrics laminating as preparation backing, the size that severing becomes to set, obtains wanted preparation.
Embodiment 6
The SIS that to get percentage by weight and be 30.9% model be JSR5505P, 24% terpene resin, 8% hydrogenated rosin glyceride, 26% liquid paraffin, 0.1% BHT, 2% MENTHOL are to blending tank, controlling temperature is 180 ℃, heating for dissolving, is uniformly mixed and makes mastic; 9% lidocaine hydrochloride is dissolved in above-mentioned mastic, is uniformly mixed and makes ointment-containing body; Ointment-containing body is uniformly coated on the polyethylene terephtalate film of processing through silicon, after looped fabric or non-woven fabrics laminating as preparation backing, the size that severing becomes to set, obtains wanted preparation.
comparative example 1
1 patch as a comparative example, is used the commercially available product (day eastern electrician's trade mark) of the lidocaine patch that contains 60%.
test example 1 crystallization test
For each preparation obtaining in above-described embodiment 1～6 and comparative example 1, be cut into the rectangle of appropriate size, paper using aluminium plastic bag is packed.Under this state, under identical temperature conditions, preserve this laminated paper aluminium plastic bag, by visual and microscopic examination adhesive phase over time, observe as the lignocaine of effective ingredient to the crystallization state in adhesive phase.
Its result is as shown in table 1.
Table 1 crystallization result of the test
Remarks :-: crystallization do not found
※: find crystallization
From the result judgement shown in table, even in the preservation of 2 months, in the preparation adhesive phase of the embodiment of the present invention 1～6, do not observe the crystallization as the lignocaine of effective ingredient.On the contrary, the patch of comparative example 1 was observed the crystallization of lignocaine after 1 week.
From above result, external use plaster of the present invention gathers the crystallization of not finding as the lignocaine of effective ingredient at adhesive phase, is extremely stable preparation.
test example 2(vitro skin permeability test-miniature pig skin test is tested)
For the vitro Drug permeability of lignocaine of the identical same medicine concentration of difference of research substrate (adhesive phase), use the present invention by embodiment 1,3 and comparative example the 1(lidocaine patch of list marketing (containing lignocaine 60%)) test by the following method.Result of the test as shown in Figure 1.
(test method)
Sample subsides are cut into applicable area and are affixed on plucked bar horse miniature pig skin of abdomen, be fixed between upper and lower two Room of diffusion cell, horny layer is (for side) upward.Built-in magnetic stirring of reception tank, add pH7.4 isotonic phosphate buffer liquid (pH7.4 phosphate buffered solution: take sodium chloride 8.0g, potassium dihydrogen phosphate 0.2g, disodium hydrogen phosphate dodecahydrate 2.9g, potassium chloride 0.2g, add water to 1000ml, with phosphorus acid for adjusting pH value, be 7.4), by in vitro transdermal device in 37 ℃ of water-baths, starting magnetic stirring apparatus constant speed stirs, in 5min, 15min, 30min, 45min, 60min, 90min different time points, acceptable solution is sampled the amount of the lignocaine seeing through by HPLC method mensuration unhairing miniature pig skin.
Result as shown in Figure 1, embodiment 1(lignocaine 10%) permeability is all higher than embodiment 3 and comparative example 1, embodiment 1 is consistent with the drug level of lignocaine in embodiment 3, but skin transit dose is different, the different adhesive phase in presentation of results the present invention sees through and has a certain impact the medicine of lignocaine.
the external apery skin of test example 3(permeability test-Strat-Membrane test)
(test method)
Because plucked bar horse miniature pig skin of abdomen thickness differs greatly, affect the result of external transit dose, in order more to approach the drug release in vitro of the lignocaine of the different same medicine concentration that embody really different adhesive phases, use the present invention that embodiment 1,3 and comparative example (lidocaine patch of list marketing (containing lignocaine 60%)) are tested by the following method.Result of the test as shown in Figure 2.
Sample subsides are cut into applicable area and are affixed on apery skin Strat-Membrane film, be fixed between upper and lower two Room of diffusion cell, horny layer is (for side) upward.Built-in magnetic stirring of reception tank, add pH7.4 isotonic phosphate buffer liquid (pH7.4 phosphate buffered solution: take sodium chloride 8.0g, potassium dihydrogen phosphate 0.2g, disodium hydrogen phosphate dodecahydrate 2.9g, potassium chloride 0.2g, add water to 1000ml, with phosphorus acid for adjusting pH value, be 7.4), by in vitro transdermal device in 37 ℃ of water-baths, starting magnetic stirring apparatus constant speed stirs, at 5min, 15min, 30min, 45min, 60min, 90min different time points samples acceptable solution, the amount of the lignocaine seeing through by HPLC method mensuration apery skin Strat-Membrane film.
As shown in Figure 2, utilize the external result that sees through of apery skin (Strat-Membrane) is consistent with the external of bar horse Corii Sus domestica through curve behavior to result, but in same time, the external transit dose of apery skin is high a lot.The permeability of embodiment 1 is all higher than embodiment 3 and comparative example 1, and embodiment 1 is consistent with the drug level of lignocaine in embodiment 3, but skin transit dose is different.Different adhesive phase in presentation of results the present invention sees through and to have a certain impact the medicine of lignocaine, and to see through trial curve trend identical with bar horse Corii Sus domestica external.
the test of test 4(vitro release)
(test method)
In order to study the drug release in vitro of the different lignocaine of substrate (adhesive phase), use the present invention by embodiment 1,3 and comparative example the 1(lidocaine patch of list marketing (containing lignocaine 60%)) test by the following method.Result of the test as shown in Figure 3.
Get 1 of this product, remove adherent layer, with on two-sided gluing and net dish, glue faces up, according to drug release determination method (< < Chinese Pharmacopoeia > > version appendix X D the 3rd method in 2010), adopt pH4.0 acetic acid/sodium acetate solution 900ml as release medium (pH4.0 acetic acid/sodium acetate solution: take anhydrous sodium acetate 1.37g, add glacial acetic acid 4.8ml, add 1000ml water, shake up, pH value is 4.0 ± 0.3), rotating speed is per minute 50 to turn, 32 ℃ of bath temperatures, respectively at 5, 10, 15, 20, 25, 30, 60, 120, 180 minutes sampling 5ml, and supplement uniform temp simultaneously, the release medium of same volume, taking out sample release solution filters with 0.45 μ m microporous filter membrane, get subsequent filtrate as test sample solution.By HPLC method, measure the accumulative releasing degree of lignocaine.
Result as shown in Figure 3, embodiment 1,3 and the accumulative releasing degree of comparative example example 1 in pH4.0 acetic acid/sodium acetate solution, the lignocaine accumulative releasing degree of enforcement 1 is put all higher than comparative example 1 at each, a little more than embodiment 3, the lignocaine accumulative releasing degree of enforcement 1 and embodiment 3 is basically identical, proves that the release behavior of lignocaine in essentially identical mastic system is basically identical.
180 ° of peeling force tests of test 5(steel adhesiveness)
(test method)
In order to study the impact on lidocaine patch viscous force characteristic of substrate (adhesive phase), use the present invention by embodiment 1, embodiment 3 and comparative example 1 totally 3 kinds of samples, by the following method 180 ° of peeling force tests of steel adhesiveness of working sample.Result of the test as shown in Figure 4.
According to peeling strength test indoor conditions temperature 2323 ± 2oC under two transdermal patch items of < < Chinese Pharmacopoeia > > version in 2010, relative humidity 50 ± 5%, concrete operations, before detecting, by ethyl acetate, thoroughly clean corrosion resistant plate face, with clean gauze, it is carefully dried, repeatedly clean 2～3 times until stainless steel surfaces is clean.Clean all detection panels before detecting; Sample thief, by the careful 0.5～1.0cm that tears of the protective layer of sample end, is bonded at mylar on the adhesive-layer of exposure, and remaining protective layer is removed when detecting; Remove the protective layer of sample, rapidly (in 15 seconds) adhere to patch on clean corrosion resistant plate, with the unidirectional roll extrusion 3 times on sample of the weight roller of 2kg, place after 30min; By 180 ° of the free end doublings of mylar, the free end of mylar and bread board are held on testing machine respectively up and down, release surface and testing machine line are consistent, utilize specific instrument setting (speed 300 ± 10 mm/min) to peel off test, and start pairing strength and carry out continual measurement, record peel force curve, only in the steady statue of test, partly assess, beginning and decline (sample length is less than 5mm conventionally) are given up.The meansigma methods of calculating 4 measurement results, unit is gf/cm.From figure, data are known, utilize 180 ° of peel force value of steel adhesiveness can directly embody the adhesion strength size of each product, and the adhesion strength compared with comparative example 1 and embodiment 1 of embodiment 3 is all large, and this result has further been verified and viscosifier consumption relation in direct ratio.
industrial applicibility
As mentioned above, patch provided by the invention is the adhesive phase of the essential composition of a kind of conduct that contains styrene isoprene styrene block copolymer (SIS) (SIS), tackifier resins and softening agent, and mixed therein the local external use's anesthesia patch as the lignocaine of effective ingredient, the present invention makes the release property steady in a long-term of lignocaine become possibility, and a kind of patch with very high medicine releasability is provided, very practical in medical treatment.
Claims (10)
1. local anesthesia external patch tablet that contains lignocaine or its pharmaceutical salts and preparation method thereof, it is the local applied paster agent of lamination adhesive layer on soft backing, it is characterized in that: described adhesive phase contains the styrene isoprene styrene block copolymer (SIS) SIS of 10～50 % by weight by weight percentage, the softening agent of the tackifying resin of 20～50 % by weight, 10～50 % by weight, antioxidant, filler, as lignocaine 5～10 % by weight of effective ingredient; Wherein the concrete model of SIS is a kind or the mixture of 2 kinds in JSR5505P or JSR5000.
2. a kind of local anesthesia external patch tablet that contains lignocaine or its pharmaceutical salts according to claim 1 and preparation method thereof, is characterized in that: it is the MENTHOL of 1～5 % by weight percentage that described adhesive phase contains.
3. a kind of local anesthesia external patch tablet that contains lignocaine or its pharmaceutical salts according to claim 1 and 2 and preparation method thereof, it is characterized in that: described tackifying resin is the mixture of alicyclic saturated hydrocarbon resin or terpene resin and hydrogenated rosin glyceride, terpene resin and hydrogenated rosin glyceride ratio is by weight 1:1～10:1.
4. a kind of local anesthesia external patch tablet that contains lignocaine or its pharmaceutical salts according to claim 1 and 2 and preparation method thereof, it is characterized in that: it is characterized in that: described softening agent is the mixture of liquid paraffin or liquid paraffin and polybutene, in the mixture of liquid paraffin and polybutene, the two ratio is by weight 3:1～10:1.
5. a kind of local anesthesia external patch tablet that contains lignocaine or its pharmaceutical salts according to claim 1 and 2 and preparation method thereof, is characterized in that: described antioxidant comprises any one in 2,6-toluene di-tert-butyl phenol BHT or vitamin E.
6. a kind of local anesthesia external patch tablet that contains lignocaine or its pharmaceutical salts according to claim 1 and 2 and preparation method thereof, is characterized in that: described filler comprises in titanium dioxide, silicon dioxide, zinc oxide, calcium carbonate, Kaolin the mixture of one or two or more kinds.
7. a preparation method of preparing the local anesthesia external patch tablet that contains lignocaine or its pharmaceutical salts claimed in claim 1, containing having the following steps:
Get styrene isoprene styrene block copolymer (SIS), tackifying resin, softening agent, MENTHOL, antioxidant and the filler of recipe quantity, controlling temperature is 120 ℃-200 ℃, and heating for dissolving, is uniformly mixed and makes mastic A;
Principal agent is dissolved in above-mentioned mastic A, is uniformly mixed and makes mastic B;
Mastic B is uniformly coated on polyethylene terephtalate film, and after looped fabric as preparation backing or non-woven fabrics laminating, the size that severing becomes to set, obtains wanted preparation.
8. the preparation method of the local anesthesia external patch tablet that preparation according to claim 7 contains lignocaine or its pharmaceutical salts, is characterized in that PET film is the film that silicon is processed.
9. the preparation method of the local anesthesia external patch tablet that preparation according to claim 7 contains lignocaine or its pharmaceutical salts, the temperature that it is characterized in that heating for dissolving is 150 ℃-180 ℃.
10. according to a kind of local anesthesia external patch tablet that contains lignocaine or its pharmaceutical salts described in claim 1 to 9 and preparation method thereof, it is characterized in that described lignocaine pharmaceutical salts comprises lidocaine hydrochloride or lignocaine carbonate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410411547.0A CN104188939B (en) | 2014-08-20 | 2014-08-20 | A kind of local topical paster agent containing lidocaine or its pharmaceutical salts |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410411547.0A CN104188939B (en) | 2014-08-20 | 2014-08-20 | A kind of local topical paster agent containing lidocaine or its pharmaceutical salts |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104188939A true CN104188939A (en) | 2014-12-10 |
| CN104188939B CN104188939B (en) | 2017-07-04 |
Family
ID=52074420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410411547.0A Active CN104188939B (en) | 2014-08-20 | 2014-08-20 | A kind of local topical paster agent containing lidocaine or its pharmaceutical salts |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104188939B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105505308A (en) * | 2015-12-19 | 2016-04-20 | 仇颖超 | Preparing method for pure natural hot-melt pressure-sensitive adhesive |
| CN106821769A (en) * | 2015-12-07 | 2017-06-13 | 北京乳凝创智生物技术研发中心（有限合伙） | New parents' gel membrane material and preparation method thereof |
| CN107028915A (en) * | 2016-02-04 | 2017-08-11 | 北京泰德制药股份有限公司 | Preparation for external application to skin containing Bupivacaine or its pharmaceutical salts |
| CN110559275A (en) * | 2019-08-26 | 2019-12-13 | 西安博和医疗科技有限公司 | Application for skin anesthesia and preparation method thereof |
| CN114288236A (en) * | 2021-12-15 | 2022-04-08 | 中国医学科学院整形外科医院 | Anesthetic ointment, preparation method and analgesic patch |
| WO2022100120A1 (en) * | 2020-11-11 | 2022-05-19 | 长沙晶易医药科技有限公司 | External preparation of lidocaine-prilocaine pharmaceutical composition and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140171509A1 (en) * | 2011-05-10 | 2014-06-19 | Oishi Koseido Co., Ltd. | Non-Aqueous Patch |
-
2014
- 2014-08-20 CN CN201410411547.0A patent/CN104188939B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140171509A1 (en) * | 2011-05-10 | 2014-06-19 | Oishi Koseido Co., Ltd. | Non-Aqueous Patch |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106821769A (en) * | 2015-12-07 | 2017-06-13 | 北京乳凝创智生物技术研发中心（有限合伙） | New parents' gel membrane material and preparation method thereof |
| CN105505308A (en) * | 2015-12-19 | 2016-04-20 | 仇颖超 | Preparing method for pure natural hot-melt pressure-sensitive adhesive |
| CN107028915A (en) * | 2016-02-04 | 2017-08-11 | 北京泰德制药股份有限公司 | Preparation for external application to skin containing Bupivacaine or its pharmaceutical salts |
| CN107028915B (en) * | 2016-02-04 | 2020-05-12 | 北京泰德制药股份有限公司 | Skin external preparation containing bupivacaine or its medicinal salt |
| CN110559275A (en) * | 2019-08-26 | 2019-12-13 | 西安博和医疗科技有限公司 | Application for skin anesthesia and preparation method thereof |
| WO2022100120A1 (en) * | 2020-11-11 | 2022-05-19 | 长沙晶易医药科技有限公司 | External preparation of lidocaine-prilocaine pharmaceutical composition and application thereof |
| CN114288236A (en) * | 2021-12-15 | 2022-04-08 | 中国医学科学院整形外科医院 | Anesthetic ointment, preparation method and analgesic patch |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104188939B (en) | 2017-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104188939A (en) | Partial external patch containing lidocaine or pharmaceutical salts thereof | |
| EP1928924B1 (en) | Acrylic polymer-based adhesives | |
| Shi et al. | A novel transdermal drug delivery system based on self-adhesive Janus nanofibrous film with high breathability and monodirectional water-penetration | |
| US9700522B2 (en) | Transdermal patch and method for delivery of vitamin B12 | |
| TWI542368B (en) | Patch containing serotonin receptor antagonist | |
| MX2014003688A (en) | Non-aqueous patch. | |
| EP1945685B1 (en) | Acrylic polymer-based adhesives | |
| JP2005506297A (en) | Pergolide transdermal delivery | |
| TWI454258B (en) | Production method of nicotine transdermal preparation | |
| CN102470131A (en) | Fentanyl-containing adhesive preparation for external use | |
| CN102379862B (en) | Spirosal-containing hydrophilic cataplasm | |
| ES2666143T3 (en) | Patch for the treatment of eyelid diseases containing clobetasol | |
| JP2009029768A (en) | Tape preparation for percutaneous absorption | |
| JP3276188B2 (en) | Patch and method for producing the same | |
| CN103301093B (en) | Testoderm | |
| CN102772417A (en) | Period effect percutaneous patch of self viscosity elastic body substrate containing testosterone and preparation method thereof | |
| JPH1149670A (en) | Percutaneously absorbable preparation for local anesthesia | |
| CN107028915B (en) | Skin external preparation containing bupivacaine or its medicinal salt | |
| KR101353478B1 (en) | Transdermal patch for administering fentanyl | |
| TW200831142A (en) | Manufacturing apparatus of transdermal absorption preparation | |
| CN103202823A (en) | Patch for treating cough and asthma and preparation thereof | |
| CN109481423A (en) | A kind of diclofenac salt transdermal patch and preparation method thereof | |
| JP4981402B2 (en) | Nicotine transdermal absorption preparation and method for producing the same | |
| WO2021037199A1 (en) | Transdermal amide local anesthetic-containing pharmaceutical composition and preparation method therefor | |
| CN109806243B (en) | A skin external patch containing flupirtine or its medicinal salt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |